Valneva advances with new phase 3 trial for Lyme vaccine

French biotech Valneva reaches a key milestone with the launch of a new phase 3 trial for its Lyme disease vaccine program.

Published 12sem1 sourceNotable

≈ 29sSpeed

The fact

This clinical advance constitutes a potential catalyst for the stock, given growing demand for prevention solutions against this emerging disease.

Success in this clinical trial could lead to regulatory approval and open a significant market in the United States and Europe.

Click the link to read an article on the topic:

Explore this topic

Auto-synthesis from 1 media source · identified on April 23, 2026